Centro Cardiologico Monzino S.p.A.
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At Centro Cardiologico Monzino S.p.A. in Milan, the strongest research focus is on cardiovascular diseases, with trials spanning atherosclerotic cardiovascular disease, heart failure, myocardial infarction, and complex inherited or inflammatory heart conditions. Many studies aim to test new treatments, reduce major cardiovascular events, and slow disease progression in people at high risk.
- Prevention of heart attacks, stroke, and other major cardiovascular events in high-risk patients
- New approaches for heart failure, including preserved, reduced, and mildly reduced ejection fraction
- Research on coronary artery disease, plaque progression, and lipid-related risk
- Studies in cardiomyopathies, aortic valve stenosis, and inflammatory heart disease
The site also investigates treatment strategies for conditions such as atrial fibrillation, hypertrophic cardiomyopathy, and transthyretin amyloid cardiomyopathy, reflecting a broad effort to improve both outcomes and long-term care.
Nutritional and Metabolic Diseases
Research in nutritional and metabolic diseases is centered on obesity, overweight, type 2 diabetes mellitus, and severe lipid disorders such as hypercholesterolemia and homozygous familial hypercholesterolemia. These trials are designed to evaluate therapies that may improve weight control, metabolic health, and cardiovascular risk at the same time.
- Weight-management studies in people with obesity or overweight
- Trials in type 2 diabetes focused on cardiovascular protection
- Lipid-lowering research for ASCVD, elevated Lp(a), and familial hypercholesterolemia
- Studies combining metabolic and heart outcomes to assess overall treatment benefit
Several projects also explore whether newer therapies can lower plaque burden, improve blood lipids, and reduce the risk of future cardiovascular complications in patients with metabolic disease.
Respiratory Tract Diseases
The respiratory tract diseases portfolio is smaller but important, with studies in acute respiratory distress syndrome and pulmonary hypertension linked to heart failure. This work focuses on improving recovery, easing symptoms, and finding better supportive or disease-modifying treatments.
- ARDS research aimed at improving outcomes in severe lung inflammation and respiratory failure
- Pulmonary hypertension studies in patients with heart failure and breathing limitation
- Trials assessing whether new therapies can improve exercise capacity and daily function
- Supportive care research in critically ill patients with serious respiratory complications
At this site, respiratory research is closely connected to cardiac care, especially where breathing disorders overlap with heart failure and reduced physical performance.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 4 therapeutic areas and 15 of 94 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 85 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 21 by active trials.
- 1AstraZeneca AB4active
lock +20 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG9trials
lock +12 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centro Cardiologico Monzino S.p.A.
lock Showing 1 of 64 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Safety, Tolerability, and Effect of Olpasiran on Coronary Artery Plaque Burden Assessed by Coronary Computed Tomography Angiography in Participants With Stable Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a) | Amgen Inc. | Phase III | Recruiting | Mar 2026 | — |
IMP list
lock Showing 1 of 94 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Inclisiran | 5 | Unknown | 2021-11-26 | 2026-02-17 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.